Cells surviving fractional killing by TRAIL exhibit transient but sustainable resistance and inflammatory phenotypes
Year: 2013
Type: article
Abstract: When clonal populations of human cells are exposed to apoptosis-inducing agents, some cells die and others survive. This fractional killing arises not from mutation but from preexisting, stochastic differences in the levels and activities of proteins regulating apoptosis. Here we examine the properties of cells that survive treatment with agonists of two distinct death receptors, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and anti-FasR antibodies. We find that "survivor" cells are highly resistant to a second ligand dose applied 1 d later. Resistance is reversible, resetting after several days of culture in the absence of death ligand. "Reset" cells appear identical to drug-naive cells with respect to death ligand sensitivity and gene expression profiles. TRAIL survivors are cross-resistant to activators of FasR and vice versa and exhibit an NF-κB-dependent inflammatory phenotype. Remarkably, reversible resistance is induced in the absence of cell death when caspase inhibitors are present and can be sustained for 1 wk or more, also without cell death, by periodic ligand exposure. Thus stochastic differences in cell state can have sustained consequences for sen-sitivity to prodeath ligands and acquisition of proinflammatory phenotypes. The important role played by periodicity in TRAIL exposure for induction of opposing apoptosis and survival mechanisms has implications for the design of optimal therapeutic agents and protocols.
Source: Molecular Biology of the Cell
Institution: Harvard University
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: green
Funders: Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, University of Leicester, National Institutes of Health, Genentech, National Cancer Institute, National Institute of General Medical Sciences, National Institute of Neurological Disorders and Stroke, National Center for Research Resources, Eunice Kennedy Shriver National Institute of Child Health and Human Development
Awards: G2360436881, Harvard Clinical and Translational Science Center (UL1), Molecular, Cellular, & Developmental Dynamics PhD Program, Mechanistic Pharmacology of Anti-Mitotics and Apoptosis Regulation, Pathogenesis and Treatment of Muscular Dystrophy, Intellectual and Developmental Disablities Research Center, Cancer Center Support (Core) Grant
OpenAlex ID: W2132672330
